Search

Your search keyword '"Layfield, Carron"' showing total 31 results
Start Over Author "Layfield, Carron"
31 results on '"Layfield, Carron"'

3. Celebrating 20 years of the UK Dermatology Clinical Trials Network. Part 1: Developing and delivering high-quality independent clinical trials

Author

Williams, Hywel C., McPhee, Margaret, Layfield, Carron, and The UK Dermatology Clinical Trials Network

Subjects
Dermatology
Abstract

The UK Dermatology Clinical Trials Network (UK DCTN) was formed in 2002 with the aim of developing and supporting high-quality independent national clinical trials that address prioritized research questions for people with skin disease. Its philosophy is to democratize UK dermatological clinical research and to tackle important clinical questions that industry has no incentive to answer. The network also plays a key role in training and capacity development. Its membership of over 1000 individuals includes dermatology consultants, trainees, dermatology nurses, general practitioners, methodologists and patients. Its organizational structures are lean and include a co-ordinating team based at the Centre of Evidence-Based Dermatology in Nottingham, and an executive with independent members to ensure probity and business progression. A prioritization panel and steering group enable a pipeline of projects to be prioritized and refined for external funding from independent sources. The UK DCTN has supported and completed 12 national clinical trials, attracting investment of over £15 million into UK clinical dermatology research. Trials have covered a range of interventions from drugs such as doxycycline (BLISTER), silk clothing for eczema (CLOTHES) and surgical interventions for hidradenitis suppurativa (THESEUS). Trial results are published in prestigious journals and have global impact. Genuine partnership with patients and carers has been a strong feature of the network since its inception. The UK DCTN is proud of its first 20 years of collaborative work, and aims to remain at the forefront of independent dermatological health technology assessment, as well as expanding into areas including diagnostics, artificial intelligence, efficient studies and innovative designs.

Published
2022

4. Celebrating 20?years of the UK Dermatology Clinical Trials Network. Part 2: education, training and capacity building

Author

Layfield, Carron P., Williams, Hywel C., and The UK Dermatology Clinical Trials Network

Subjects
Dermatology
Abstract

In Part 1 of this 2-part review of the 20th anniversary of the UK Dermatology Clinical Trials Network (UK DCTN), we described its role in developing and supporting clinical trial proposals, elaborating on structure, process and clinical trials activity. This review describes the diverse educational and training activities that the UK DCTN supports. Although not primarily set up as an educational organization, an education and training function emerged organically as the network grew. Education and training also embodies the democratization principle that drove the formation of the UK DCTN, allowing participation from a much wider group of individuals than just senior academics. Far from being a sideline, education and training has now become a major component of the UK DCTN that evolves constantly through changing training curricula and trial methodology developments. Formal UK DCTN training opportunities started in 2007 with competitively awarded annual fellowships for dermatology trainees, followed by similar schemes for general practitioners, Staff and Associate Specialist clinicians and dermatology nurses. These were followed in 2013 by larger groups of trainees who work up specific trial proposals with senior mentors. Finally, a virtual journal club emerged during the pandemic in 2020 in order to reach trainees with little access to academic training. Focused activities with dermatological nurses and patients/carers also take place. Such activities require considerable organization and volunteerism from the co-ordinating centre and former fellows. Education and training has become an essential component for capacity building to develop clinical trials and succession planning for the UK DCTN.

Published
2022

8. Celebrating 20 years of the UK Dermatology Clinical Trials Network. Part 2: education, training and capacity building.

Author

Layfield, Carron P. and Williams, Hywel C.

Subjects
*CLINICAL trials, *GENERAL practitioners, *DERMATOLOGY, *NURSES as patients, *COVID-19 pandemic, *DERMATOLOGISTS, *DERMATOLOGIC nursing
Abstract

Summary: In Part 1 of this 2‐part review of the 20th anniversary of the UK Dermatology Clinical Trials Network (UK DCTN), we described its role in developing and supporting clinical trial proposals, elaborating on structure, process and clinical trials activity. This review describes the diverse educational and training activities that the UK DCTN supports. Although not primarily set up as an educational organization, an education and training function emerged organically as the network grew. Education and training also embodies the democratization principle that drove the formation of the UK DCTN, allowing participation from a much wider group of individuals than just senior academics. Far from being a sideline, education and training has now become a major component of the UK DCTN that evolves constantly through changing training curricula and trial methodology developments. Formal UK DCTN training opportunities started in 2007 with competitively awarded annual fellowships for dermatology trainees, followed by similar schemes for general practitioners, Staff and Associate Specialist clinicians and dermatology nurses. These were followed in 2013 by larger groups of trainees who work up specific trial proposals with senior mentors. Finally, a virtual journal club emerged during the pandemic in 2020 in order to reach trainees with little access to academic training. Focused activities with dermatological nurses and patients/carers also take place. Such activities require considerable organization and volunteerism from the co‐ordinating centre and former fellows. Education and training has become an essential component for capacity building to develop clinical trials and succession planning for the UK DCTN. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

10. UK DERMATOLOGY CLINICAL TRIALS NETWORK (UKDCTN) UPDATE.

Author

Layfield, Carron

Subjects
SKIN diseases, DERMATOLOGIC nursing, CLINICAL trials, ACNE, ECZEMA, HUMAN research subjects, PATIENT selection, INVESTIGATIONAL drugs, MEMBERSHIP, INFORMATION resources, WORLD Wide Web
Published
2023

11. UK DERMATOLOGY CLINICAL TRIALS NETWORK (UK DCTN) UPDATE.

Author

Layfield, Carron

Subjects
CLINICAL trials, ECZEMA, HUMAN research subjects, DERMATOLOGY, PATIENT selection, EXECUTIVES, INVESTIGATIONAL drugs, BUSINESS networks, INFORMATION resources, MEDICAL fellowships, FOOD allergy
Published
2023

12. A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease

Author

Thomas, Kim S, primary, Batchelor, Jonathan M, additional, Bath-Hextall, Fiona, additional, Chalmers, Joanne R, additional, Clarke, Tessa, additional, Crowe, Sally, additional, Delamere, Finola M, additional, Eleftheriadou, Viktoria, additional, Evans, Nicholas, additional, Firkins, Lester, additional, Greenlaw, Nicola, additional, Lansbury, Louise, additional, Lawton, Sandra, additional, Layfield, Carron, additional, Leonardi-Bee, Jo, additional, Mason, James, additional, Mitchell, Eleanor, additional, Nankervis, Helen, additional, Norrie, John, additional, Nunn, Andrew, additional, Ormerod, Anthony D, additional, Patel, Ramesh, additional, Perkins, William, additional, Ravenscroft, Jane C, additional, Schmitt, Jochen, additional, Simpson, Eric, additional, Whitton, Maxine E, additional, and Williams, Hywel C, additional

Published
2016
Full Text
View/download PDF

16. PUTTING UK DCTN STUDIES INTO PRACTICE: A NURSE AND PATIENT PERSPECTIVE OF THE INVESTIGATOR DAY FOR THE BLISTER AND STOP GAP TRIALS.

Author

Westmoreland, Melanie, Burden-Teh, Esther, Layfield, Carron, and Thompson, Ingrid

Subjects
CYCLOSPORINE, PYODERMA gangrenosum, BULLOUS pemphigoid, PREDNISOLONE, BLISTERS, CLINICAL trials, INTERPROFESSIONAL relations, NURSES' attitudes, TREATMENT effectiveness, PATIENTS' attitudes, THERAPEUTICS
Abstract

This article looks at the outcome of two clinical trials - the BLISTER and STOP GAP studies. These trials investigated treatments routinely available in dermatology and focused on rarer skin diseases - bullous pemphigoid and pyoderma gangrenosum. [ABSTRACT FROM AUTHOR]

Published
2017

17. UK DERMATOLOGY CLINICAL TRIALS NETWORK (UK DCTN) UPDATE.

Author

Layfield, Carron and McPhee, Margaret

Subjects
ACNE, CLINICAL medicine research, CLINICAL trials, DERMATOLOGY, ECZEMA, INTERPROFESSIONAL relations, PHOTOTHERAPY, PRESS, VITILIGO, HIDRADENITIS suppurativa
Published
2020

19. Newly funded studies.

Author

Layfield, Carron

Subjects
EVALUATION of medical care, ECZEMA, COST effectiveness, CLINICAL medicine
Published
2021

21. UK DERMATOLOGY CLINICAL TRIALS NETWORK: UPDATE ON ACTIVITIES.

Author

Layfield, Carron and McPhee, Margaret

Subjects
AWARDS, CELL receptors, DERMATOLOGIC nursing, ECZEMA, INTERLEUKIN-1, PHOTOCHEMOTHERAPY, PSORIASIS, SPIRONOLACTONE, TRETINOIN, ACNEIFORM eruptions, HIDRADENITIS suppurativa, ADULTS
Published
2020

23. UK DCTN UPDATE.

Author

Layfield, Carron

Subjects
ATOPIC dermatitis treatment, DERMATOLOGIC nursing, COMMITTEES, PROFESSIONAL employee training, AWARDS, INFORMATION resources, WORLD Wide Web, ADULTS
Published
2021

24. UK DERMATOLOGY CLINICAL TRIALS NETWORK (UK DCTN) UPDATE.

Author

Layfield, Carron and McPhee, Margaret

Subjects
DERMATOLOGIC nursing, APRICOT, BONE diseases, CONFERENCES & conventions, DERMATOLOGIC agents, DEVELOPMENTAL disabilities, ECZEMA, PROFESSIONAL practice, MEMBERSHIP, SOCIETIES
Published
2019

26. A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease

Author

Thomas, Kim S., Batchelor, Jonathan M., Bath-Hextall, Fiona, Chalmers, Joanne, Clarke, Tessa, Crowe, Sally, Delamere, Finola M., Eleftheriadou, Viktoria, Evans, Nicholas, Firkins, Lester, Greenlaw, Nicola, Lansbury, Louise E., Lawton, Sandra, Layfield, Carron, Leonardi-Bee, Jo, Mason, James, Mitchell, Eleanor, Nankervis, Helen, Norrie, John, Nunn, Andrew, Ormerod, Anthony D., Patel, Ramesh, Perkins, William, Ravenscroft, Jane C., Schmitt, Jochen, Simpson, Eric, Whitton, Maxine E., Williams, Hywel C., Thomas, Kim S., Batchelor, Jonathan M., Bath-Hextall, Fiona, Chalmers, Joanne, Clarke, Tessa, Crowe, Sally, Delamere, Finola M., Eleftheriadou, Viktoria, Evans, Nicholas, Firkins, Lester, Greenlaw, Nicola, Lansbury, Louise E., Lawton, Sandra, Layfield, Carron, Leonardi-Bee, Jo, Mason, James, Mitchell, Eleanor, Nankervis, Helen, Norrie, John, Nunn, Andrew, Ormerod, Anthony D., Patel, Ramesh, Perkins, William, Ravenscroft, Jane C., Schmitt, Jochen, Simpson, Eric, Whitton, Maxine E., and Williams, Hywel C.

Abstract

Background Skin diseases are very common and can have a large impact on the quality of life of patients and caregivers. This programme addressed four diseases: (1) eczema, (2) vitiligo, (3) squamous cell skin cancer (SCC) and (4) pyoderma gangrenosum (PG). Objective To set priorities and reduce uncertainties for the treatment and prevention of skin disease in our four chosen diseases. Design Mixed methods including eight systematic reviews, three prioritisation exercises, two pilot randomised controlled trials (RCTs), three feasibility studies, two core outcome initiatives, four funding proposals for national RCTs and one completed national RCT. Setting Secondary care, primary care and the general population. Participants Patients (and their caregivers) with eczema, vitiligo, SCC and PG, plus health-care professionals with an interest in skin disease. Interventions Our three intervention studies included (1) barrier enhancement using emollients from birth to prevent eczema (pilot RCT); (2) handheld narrowband ultraviolet light B therapy for treating vitiligo (pilot RCT); and (3) oral ciclosporin (Neoral®, Novartis Pharmaceuticals) compared with oral prednisolone for managing PG (pragmatic national RCT). Results Systematic reviews included two overarching systematic reviews of RCTs of treatments for eczema and vitiligo, an umbrella review of systematic reviews of interventions for the prevention of eczema, two reviews of treatments for SCC (one included RCTs and the second included observational studies), and three reviews of outcome measures and outcome reporting. Three prioritisation partnership exercises identified 26 priority areas for future research in eczema, vitiligo and SCC. Two international consensus initiatives identified four core domains for future eczema trials and seven core domains for vitiligo trials. Two pilot RCTs and three feasibility studies critically informed development of four trial proposals for external funding, three of which are now fund

Full Text
View/download PDF

27. A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease

Author

Thomas, Kim S., Batchelor, Jonathan M., Bath-Hextall, Fiona, Chalmers, Joanne, Clarke, Tessa, Crowe, Sally, Delamere, Finola M., Eleftheriadou, Viktoria, Evans, Nicholas, Firkins, Lester, Greenlaw, Nicola, Lansbury, Louise E., Lawton, Sandra, Layfield, Carron, Leonardi-Bee, Jo, Mason, James, Mitchell, Eleanor, Nankervis, Helen, Norrie, John, Nunn, Andrew, Ormerod, Anthony D., Patel, Ramesh, Perkins, William, Ravenscroft, Jane C., Schmitt, Jochen, Simpson, Eric, Whitton, Maxine E., Williams, Hywel C., Thomas, Kim S., Batchelor, Jonathan M., Bath-Hextall, Fiona, Chalmers, Joanne, Clarke, Tessa, Crowe, Sally, Delamere, Finola M., Eleftheriadou, Viktoria, Evans, Nicholas, Firkins, Lester, Greenlaw, Nicola, Lansbury, Louise E., Lawton, Sandra, Layfield, Carron, Leonardi-Bee, Jo, Mason, James, Mitchell, Eleanor, Nankervis, Helen, Norrie, John, Nunn, Andrew, Ormerod, Anthony D., Patel, Ramesh, Perkins, William, Ravenscroft, Jane C., Schmitt, Jochen, Simpson, Eric, Whitton, Maxine E., and Williams, Hywel C.

Abstract

Background Skin diseases are very common and can have a large impact on the quality of life of patients and caregivers. This programme addressed four diseases: (1) eczema, (2) vitiligo, (3) squamous cell skin cancer (SCC) and (4) pyoderma gangrenosum (PG). Objective To set priorities and reduce uncertainties for the treatment and prevention of skin disease in our four chosen diseases. Design Mixed methods including eight systematic reviews, three prioritisation exercises, two pilot randomised controlled trials (RCTs), three feasibility studies, two core outcome initiatives, four funding proposals for national RCTs and one completed national RCT. Setting Secondary care, primary care and the general population. Participants Patients (and their caregivers) with eczema, vitiligo, SCC and PG, plus health-care professionals with an interest in skin disease. Interventions Our three intervention studies included (1) barrier enhancement using emollients from birth to prevent eczema (pilot RCT); (2) handheld narrowband ultraviolet light B therapy for treating vitiligo (pilot RCT); and (3) oral ciclosporin (Neoral®, Novartis Pharmaceuticals) compared with oral prednisolone for managing PG (pragmatic national RCT). Results Systematic reviews included two overarching systematic reviews of RCTs of treatments for eczema and vitiligo, an umbrella review of systematic reviews of interventions for the prevention of eczema, two reviews of treatments for SCC (one included RCTs and the second included observational studies), and three reviews of outcome measures and outcome reporting. Three prioritisation partnership exercises identified 26 priority areas for future research in eczema, vitiligo and SCC. Two international consensus initiatives identified four core domains for future eczema trials and seven core domains for vitiligo trials. Two pilot RCTs and three feasibility studies critically informed development of four trial proposals for external funding, three of which are now fund

Full Text
View/download PDF

28. A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease

Author

Thomas, Kim S., Batchelor, Jonathan M., Bath-Hextall, Fiona, Chalmers, Joanne, Clarke, Tessa, Crowe, Sally, Delamere, Finola M., Eleftheriadou, Viktoria, Evans, Nicholas, Firkins, Lester, Greenlaw, Nicola, Lansbury, Louise E., Lawton, Sandra, Layfield, Carron, Leonardi-Bee, Jo, Mason, James, Mitchell, Eleanor, Nankervis, Helen, Norrie, John, Nunn, Andrew, Ormerod, Anthony D., Patel, Ramesh, Perkins, William, Ravenscroft, Jane C., Schmitt, Jochen, Simpson, Eric, Whitton, Maxine E., Williams, Hywel C., Thomas, Kim S., Batchelor, Jonathan M., Bath-Hextall, Fiona, Chalmers, Joanne, Clarke, Tessa, Crowe, Sally, Delamere, Finola M., Eleftheriadou, Viktoria, Evans, Nicholas, Firkins, Lester, Greenlaw, Nicola, Lansbury, Louise E., Lawton, Sandra, Layfield, Carron, Leonardi-Bee, Jo, Mason, James, Mitchell, Eleanor, Nankervis, Helen, Norrie, John, Nunn, Andrew, Ormerod, Anthony D., Patel, Ramesh, Perkins, William, Ravenscroft, Jane C., Schmitt, Jochen, Simpson, Eric, Whitton, Maxine E., and Williams, Hywel C.

Abstract

Background Skin diseases are very common and can have a large impact on the quality of life of patients and caregivers. This programme addressed four diseases: (1) eczema, (2) vitiligo, (3) squamous cell skin cancer (SCC) and (4) pyoderma gangrenosum (PG). Objective To set priorities and reduce uncertainties for the treatment and prevention of skin disease in our four chosen diseases. Design Mixed methods including eight systematic reviews, three prioritisation exercises, two pilot randomised controlled trials (RCTs), three feasibility studies, two core outcome initiatives, four funding proposals for national RCTs and one completed national RCT. Setting Secondary care, primary care and the general population. Participants Patients (and their caregivers) with eczema, vitiligo, SCC and PG, plus health-care professionals with an interest in skin disease. Interventions Our three intervention studies included (1) barrier enhancement using emollients from birth to prevent eczema (pilot RCT); (2) handheld narrowband ultraviolet light B therapy for treating vitiligo (pilot RCT); and (3) oral ciclosporin (Neoral®, Novartis Pharmaceuticals) compared with oral prednisolone for managing PG (pragmatic national RCT). Results Systematic reviews included two overarching systematic reviews of RCTs of treatments for eczema and vitiligo, an umbrella review of systematic reviews of interventions for the prevention of eczema, two reviews of treatments for SCC (one included RCTs and the second included observational studies), and three reviews of outcome measures and outcome reporting. Three prioritisation partnership exercises identified 26 priority areas for future research in eczema, vitiligo and SCC. Two international consensus initiatives identified four core domains for future eczema trials and seven core domains for vitiligo trials. Two pilot RCTs and three feasibility studies critically informed development of four trial proposals for external funding, three of which are now fund

Full Text
View/download PDF

29. A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease

Author

Thomas, Kim S., Batchelor, Jonathan M., Bath-Hextall, Fiona, Chalmers, Joanne, Clarke, Tessa, Crowe, Sally, Delamere, Finola M., Eleftheriadou, Viktoria, Evans, Nicholas, Firkins, Lester, Greenlaw, Nicola, Lansbury, Louise E., Lawton, Sandra, Layfield, Carron, Leonardi-Bee, Jo, Mason, James, Mitchell, Eleanor, Nankervis, Helen, Norrie, John, Nunn, Andrew, Ormerod, Anthony D., Patel, Ramesh, Perkins, William, Ravenscroft, Jane C., Schmitt, Jochen, Simpson, Eric, Whitton, Maxine E., Williams, Hywel C., Thomas, Kim S., Batchelor, Jonathan M., Bath-Hextall, Fiona, Chalmers, Joanne, Clarke, Tessa, Crowe, Sally, Delamere, Finola M., Eleftheriadou, Viktoria, Evans, Nicholas, Firkins, Lester, Greenlaw, Nicola, Lansbury, Louise E., Lawton, Sandra, Layfield, Carron, Leonardi-Bee, Jo, Mason, James, Mitchell, Eleanor, Nankervis, Helen, Norrie, John, Nunn, Andrew, Ormerod, Anthony D., Patel, Ramesh, Perkins, William, Ravenscroft, Jane C., Schmitt, Jochen, Simpson, Eric, Whitton, Maxine E., and Williams, Hywel C.

Abstract

Background Skin diseases are very common and can have a large impact on the quality of life of patients and caregivers. This programme addressed four diseases: (1) eczema, (2) vitiligo, (3) squamous cell skin cancer (SCC) and (4) pyoderma gangrenosum (PG). Objective To set priorities and reduce uncertainties for the treatment and prevention of skin disease in our four chosen diseases. Design Mixed methods including eight systematic reviews, three prioritisation exercises, two pilot randomised controlled trials (RCTs), three feasibility studies, two core outcome initiatives, four funding proposals for national RCTs and one completed national RCT. Setting Secondary care, primary care and the general population. Participants Patients (and their caregivers) with eczema, vitiligo, SCC and PG, plus health-care professionals with an interest in skin disease. Interventions Our three intervention studies included (1) barrier enhancement using emollients from birth to prevent eczema (pilot RCT); (2) handheld narrowband ultraviolet light B therapy for treating vitiligo (pilot RCT); and (3) oral ciclosporin (Neoral®, Novartis Pharmaceuticals) compared with oral prednisolone for managing PG (pragmatic national RCT). Results Systematic reviews included two overarching systematic reviews of RCTs of treatments for eczema and vitiligo, an umbrella review of systematic reviews of interventions for the prevention of eczema, two reviews of treatments for SCC (one included RCTs and the second included observational studies), and three reviews of outcome measures and outcome reporting. Three prioritisation partnership exercises identified 26 priority areas for future research in eczema, vitiligo and SCC. Two international consensus initiatives identified four core domains for future eczema trials and seven core domains for vitiligo trials. Two pilot RCTs and three feasibility studies critically informed development of four trial proposals for external funding, three of which are now fund

Full Text
View/download PDF

31. Celebrating 20 years of the UK Dermatology Clinical Trials Network. Part 1: Developing and delivering high-quality independent clinical trials.

Author

Williams HC, McPhee MJ, and Layfield CP

Subjects
Artificial Intelligence, Caregivers, Clinical Trials as Topic, Humans, United Kingdom, Dermatology, Eczema
Abstract

The UK Dermatology Clinical Trials Network (UK DCTN) was formed in 2002 with the aim of developing and supporting high-quality independent national clinical trials that address prioritized research questions for people with skin disease. Its philosophy is to democratize UK dermatological clinical research and to tackle important clinical questions that industry has no incentive to answer. The network also plays a key role in training and capacity development. Its membership of over 1000 individuals includes dermatology consultants, trainees, dermatology nurses, general practitioners, methodologists and patients. Its organizational structures are lean and include a co-ordinating team based at the Centre of Evidence-Based Dermatology in Nottingham, and an executive with independent members to ensure probity and business progression. A prioritization panel and steering group enable a pipeline of projects to be prioritized and refined for external funding from independent sources. The UK DCTN has supported and completed 12 national clinical trials, attracting investment of over £15 million into UK clinical dermatology research. Trials have covered a range of interventions from drugs such as doxycycline (BLISTER), silk clothing for eczema (CLOTHES) and surgical interventions for hidradenitis suppurativa (THESEUS). Trial results are published in prestigious journals and have global impact. Genuine partnership with patients and carers has been a strong feature of the network since its inception. The UK DCTN is proud of its first 20 years of collaborative work, and aims to remain at the forefront of independent dermatological health technology assessment, as well as expanding into areas including diagnostics, artificial intelligence, efficient studies and innovative designs., (© 2022 The Authors. Clinical and Experimental Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results